Videos

Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence. 

An expert panel discusses the challenges of detecting and managing biochemical recurrence in the context of oligometastatic prostate cancer. 

Dr Munir Ghesani reviews and comments on data regarding the sensitivity of imaging modalities in detecting biochemical recurrence in prostate cancer. 

Kretschmer highlights how ongoing research is aiming to optimize use of this noninvasive, urine-based genomic test.

The rationale for utilizing fluoroscopic imaging as well as other evolving technologies that are currently being developed and explored in urology.

Reactions to advances in the quality and safety of newer imaging tests used in prostate cancer.

“Suicide is a disproportionate cause of mortality in physicians,” Pruthi says.

Dr Brad Schwartz comments on his satisfaction with current imaging systems used in urology and the impact of image quality on treatment decisions and clinical outcomes.

Dr Raoul Concepcion leads a panel discussion on a case of a 64-year-old man with multifocal prostate cancer treated with IMRT who refused ADT. 

The ExoDx Prostate test helps physicians determine whether a prostate biopsy is necessary when PSA screening is ambiguous.

Munir Ghesani, MD, an expert in nuclear medicine, describes the factors that differentiate available tracers and provides guidance on tracer selection. 

Brad Schwartz, DO, FACS, comments on radiation exposure associated with imaging assessments used in urology and explains what he and colleagues are doing to minimize exposure and address patient concerns.

On overview of the current types of imaging assessments available to diagnose and manage patients with a urological disease.

An expert panel reacts to polling data on choice of imaging modalities for patients with prostate patients after definitive therapy and share their insights about best practices.  

In terms of physician burnout, “The pandemic has only made a bad situation worse,” says Raj S. Pruthi, MD, MHA, FACS.

Raoul Concepcion, MD, presents the case of a 58-year-old man who had a radical prostatectomy 6 months prior and discusses how aspects of the case influence treatment selection. 

Frontline immune checkpoint inhibitor therapy may improve overall survival in this setting.

Around the Practice: Metastatic Castrate Resistant Prostate Cancer

Around the Practice: High-Risk Renal Cell Carcinoma

Loeb and Stork offer pointers for beginners and current users alike.

“I think one of the issues that we face as physicians…is during training, long hours and a lack of control over our schedule indoctrinates surgeons with habits that may be counterproductive to achieving life balance after entering practice,” says Raj S. Pruthi, MD, MHA FACS.

Galsky highlights final OS data from the IMvigor130 trial, along with an exploratory analysis examining outcomes by type of chemotherapy used.

Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence. 

Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer. 

Jason Zhu, MD, discusses factors he considers when choosing treatment for patients with lymph node–positive prostate cancer after prostatectomy.

Attorneys Acacia Brush Perko, Esq, and Kenton H. Steele, Esq, provide an overview of malpractice claims.

Dr Judd Moul and colleagues discuss best practices for monitoring patients with prostate cancer after definitive therapy. 

Dr Raoul Concepcion leads a panel of experts in prostate cancer in setting the stage for case-based discussions of biochemical recurrence.

Ward's analysis includes a discussion of adjuvant radiotherapy versus early salvage radiotherapy.

“This paper shows that our efforts to reduce… opioid exposure in the postoperative setting is reducing new persistent opioid use,” says Matthew S. Lee, MD.